PREVENTING MDR GRAM-NEGATIVE HOSPITAL ACQUIRED INFECTIONS

Descripción

Unmet Need:

Hospital acquired infections are leading cause of non-cardiac death in intensive care units (ICUs).

Proposed Solution:

New synthetic glycoconjugate preventing (ICU)-acquired infections by eliciting protective immunity against MDR bacteria.

Highlights

  • Synthetic polymer able to elicit  protective immunity against MDR

  • Faster developed immunity than vaccines

  • Cost-effective treatment resulting in potential savings to the health system 

Aplicaciones

The present invention relates to the field of therapeutics and, more in

particular, to agents and compositions for the prevention and/or

treatment of infections caused by bacteria. But the group is currently

working in other applications of interest.

Estado de protección

The study has shown that removal of anti-Gal

antibodies mediated by GAS prevents sepsis and reduces cytokine levels

in mice genetically modified so as to express anti-Gal antibodies.

It

has also been tested successfully in human serum, showing increased

bactericidal capacity in GAS-pre-treated serums. Toxicity preclinical

studies in house have been performed in primates successfully.

IP status: patent ongoing in national phases